drugset
drugset / Trial / NCT07305363

Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).

NCT07305363 ↗

Phase 2 Not yet recruiting 10 enrolled University of California, San Diego
NaSingle-groupOpen-labelTreatment

Summary

A prospective, open-label, single-arm, investigator-initiated study (SELIC) to evaluate the efficacy and safety of seladelpar in adult liver transplant recipients with Ischemic cholangiopathy (IC).

Timeline

Start
2026-05
Primary completion
2027-09
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Seladelpar Small molecule 10 mg Oral

Indications

non-neoplastic bile duct disorder